Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Locally Advanced Metastatic NSCLC”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Active Not RecruitingNCT04538664
What this trial is testing

Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 308
Testing effectiveness (Phase 2)Study completedNCT05519865
What this trial is testing

Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Chipscreen Biosciences, Ltd. 118
Early research (Phase 1)Active Not RecruitingNCT05919537
What this trial is testing

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

Who this might be right for
Non-Small Cell Lung CancerPancreatic CancerLocally Advanced Solid Tumor+1 more
Hummingbird Bioscience 68
Large-scale testing (Phase 3)Looking for participantsNCT06930794
What this trial is testing

Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive

Who this might be right for
Non-Small Cell Lung Cancer
Beijing Pearl Biotechnology Limited Liability Company 300
Testing effectiveness (Phase 2)Active Not RecruitingNCT03778229
What this trial is testing

Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib

Who this might be right for
Carcinoma
AstraZeneca 367
Large-scale testing (Phase 3)Looking for participantsNCT07217301
What this trial is testing

A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer

Who this might be right for
IO-resistant sqNSCLC
Takeda 600
Post-approval studies (Phase 4)Not Yet RecruitingNCT07671560
What this trial is testing

Efficacy and Safety of Ensartinib Combined With Anlotinib in Lorlatinib-Resistant ALK-Positive NSCLC

Who this might be right for
ALK-positive, Locally Advanced or Metastatic (TNM Stage IIIB-IV) Non-small Cell Lung Cancer That Has Developed Resistance to Prior Treatment With Lorlatinib
Qiming Wang 80
Testing effectiveness (Phase 2)Looking for participantsNCT07452224
What this trial is testing

ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
iLeukon Therapeutics, Inc. 80
Large-scale testing (Phase 3)Ended earlyNCT04921358
What this trial is testing

Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
BeiGene 377
Testing effectiveness (Phase 2)Looking for participantsNCT06975410
What this trial is testing

Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors

Who this might be right for
EGFR OverexpressionLocally Advanced Solid TumorMetastatic Solid Tumor
Yuhan Corporation 80
Early research (Phase 1)Looking for participantsNCT06545331
What this trial is testing

Study of XB010 in Subjects With Solid Tumors

Who this might be right for
Locally Advanced or Metastatic Solid TumorsEsophageal Squamous Cell CancerHead and Neck Squamous Cell Cancer+3 more
Exelixis 396
Testing effectiveness (Phase 2)Study completedNCT03909971
What this trial is testing

Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Pfizer 109
Large-scale testing (Phase 3)Study completedNCT00087711
What this trial is testing

Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Carcinoma
Eli Lilly and Company 1,713
Testing effectiveness (Phase 2)Study completedNCT00370292
What this trial is testing

Dosage Schedule Study of Pemetrexed Monochemotherapy for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non Small Cell Lung Cancer
Eli Lilly and Company 19
Large-scale testing (Phase 3)Temporarily pausedNCT05378763
What this trial is testing

Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations

Who this might be right for
NSCLC
Spectrum Pharmaceuticals, Inc 268
Large-scale testing (Phase 3)Looking for participantsNCT06758401
What this trial is testing

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Who this might be right for
Non-Small Cell Lung CancerCarcinoma, Non-Small-Cell LungCarcinoma, Non-Small-Cell Lung (NSCLC)
Pfizer 714
Large-scale testing (Phase 3)Not Yet RecruitingNCT07756645
What this trial is testing

Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants

Who this might be right for
Non-Small Cell Lung Cancer
AbbVie 940
Testing effectiveness (Phase 2)Looking for participantsNCT05473156
What this trial is testing

Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies

Who this might be right for
Locally Advanced or Metastatic Solid TumorsNon Small Cell Lung Cancer (NSCLC)Head and Neck Squamous Cell Carcinoma (HNSCC)+1 more
AP Biosciences Inc. 168
Post-approval studies (Phase 4)Ended earlyNCT00536107
What this trial is testing

Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
AstraZeneca 14
Large-scale testing (Phase 3)Active Not RecruitingNCT06670196
What this trial is testing

SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 420
Next Page